Assessing the Cardiac Safety of a Multimodal Protocol for 'Tranq Dope' Withdrawal: A Retrospective QTc Analysis

BACKGROUND: "Tranq dope"-fentanyl adulterated with xylazine-has complicated the management of opioid withdrawal in emergency departments (EDs). A novel withdrawal protocol was implemented to address these challenges, utilizing concurrent agents to intentionally synergize and potentiate effects. Questions remain about the safety of its components, some of which may prolong the QT interval. METHODS: We conducted a retrospective cohort study of adult ED patients with suspected fentanyl/xylazine exposure treated utilizing novel protocol across two urban hospitals in Philadelphia, PA between September 2022 and October 2024. Patients with both pre- and post-treatment electrocardiograms (ECGs) were included. QTc intervals were reviewed by an experienced cardiac electrophysiologist. The primary outcome was QTc change after treatment exposure. Secondary outcomes included symptom improvement (measured by Clinical Opiate Withdrawal Scale [COWS]), medication-specific QTc effects, adverse events, and hospital disposition. RESULTS: 1375 patients received protocol medications. 284 had pre- and post-treatment ECGs. Mean age 39 years; 62.3 % male. Nearly all tested positive for fentanyl (98.5 %), most cocaine (63.8 %). Mean QTc changed from 457 ms (pre) to 456 ms post-treatment. No protocol medication was associated with QTc prolongation. Vancomycin (+13 ms), ondansetron (+16 ms), and methadone (+15 ms) were independently associated with QTc increase in adjusted models. COWS scores improved significantly (mean reduction 10 points, p < 0.001), and no life-threatening arrhythmias were observed. CONCLUSION: The use of a multi-agent 'tranq dope' withdrawal protocol was not associated with serious adverse events. Pre and post-treatment QTc were variable but overall effects were neutral. These findings suggest these treatments can be used in those at risk, or with known QTc prolongation, though more study is needed to confirm findings.

Publication Details

Journal
The Medicine Forum
Published
2025-10-17
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessing the Cardiac Safety of a Multimodal Protocol for 'Tranq Dope' Withdrawal: A Retrospective QTc Analysis

The Medicine Forum
Opioid Use Disorder Treatment
article

Assessing the Cardiac Safety of a Multimodal Protocol for 'Tranq Dope' Withdrawal: A Retrospective QTc Analysis

article en

Abstract

BACKGROUND: "Tranq dope"-fentanyl adulterated with xylazine-has complicated the management of opioid withdrawal in emergency departments (EDs). A novel withdrawal protocol was implemented to address these challenges, utilizing concurrent agents to intentionally synergize and potentiate effects. Questions remain about the safety of its components, some of which may prolong the QT interval. METHODS: We conducted a retrospective cohort study of adult ED patients with suspected fentanyl/xylazine exposure treated utilizing novel protocol across two urban hospitals in Philadelphia, PA between September 2022 and October 2024. Patients with both pre- and post-treatment electrocardiograms (ECGs) were included. QTc intervals were reviewed by an experienced cardiac electrophysiologist. The primary outcome was QTc change after treatment exposure. Secondary outcomes included symptom improvement (measured by Clinical Opiate Withdrawal Scale [COWS]), medication-specific QTc effects, adverse events, and hospital disposition. RESULTS: 1375 patients received protocol medications. 284 had pre- and post-treatment ECGs. Mean age 39 years; 62.3 % male. Nearly all tested positive for fentanyl (98.5 %), most cocaine (63.8 %). Mean QTc changed from 457 ms (pre) to 456 ms post-treatment. No protocol medication was associated with QTc prolongation. Vancomycin (+13 ms), ondansetron (+16 ms), and methadone (+15 ms) were independently associated with QTc increase in adjusted models. COWS scores improved significantly (mean reduction 10 points, p < 0.001), and no life-threatening arrhythmias were observed. CONCLUSION: The use of a multi-agent 'tranq dope' withdrawal protocol was not associated with serious adverse events. Pre and post-treatment QTc were variable but overall effects were neutral. These findings suggest these treatments can be used in those at risk, or with known QTc prolongation, though more study is needed to confirm findings.

The Medicine Forum
Good health and well-being
Openalex Percentile: Top 31%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.